Market Intelligence, Clinical Progress, and High-Purity Reagents for Ovarian, Lung, and Phosphate Transport Modulation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SLC34A2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Protein) | SLC34A2 Large Extracellular Loop-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SLC34A2 Products |
| Full-Length Lentivirus | SLC34A2 Full-Length Lentivirus HEK293T packaged, native glycosylation, 11-TM topology preserved. Sequence Verified. |
View SLC34A2 Products |
| Gene Delivery | SLC34A2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for complex membrane target conformation. Codon-optimized, Endotoxin Controlled. |
View SLC34A2 Products |
| Benchmark Ab | Anti-SLC34A2 Recombinant Antibody (Sequence of Upifitamab) Recombinant positive control. Sequence Verified, Human IgG1 framework. |
View SLC34A2 Products |
| Validator | SLC34A2 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. HPLC purified. |
View SLC34A2 Products |
| Related Target A | FOLR1 Synergistic target often co-expressed in ovarian cancer. |
View FOLR1 Products |
| Related Target B | MUC16 Key ovarian cancer biomarker for combination therapeutic strategies. |
View MUC16 Products |
| Related Target C | SLC34A1 (NPT2a) Kidney-specific isoform for selectivity counter-screening. |
View SLC34A1 Products |
| Related Target D | SLC20A1 (PiT-1) Phosphate transporter family member, viral receptor function. |
View SLC20A1 Products |
| Related Target E | SLC34A3 Intestinal/kidney isoform for family-wide specificity panels. |
View SLC34A3 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| 11-Transmembrane Topology Preservation & Native Conformation | Full-Length SLC34A2 Lentivirus for Stable Cell Lines; native conformation in HEK293T (Endotoxin <1EU/µg). Also offers Large Extracellular Loop-Fc protein for early screening. |
| Kidney Isoform SLC34A1 Selectivity | Human/Mouse/Cyno Ortholog Panel: SLC34A2 vs SLC34A1 proteins available with >95% purity, Sequence Verified by Mass Spec. |
| Phosphate Uptake Functional Validation | Transport-Competent Stable Cell Lines; Validated for Na+-dependent phosphate cotransport assay compatibility. |
| Cross-Species Toxicology Evaluation | Cyno SLC34A2 Lentivirus & Protein available; Critical for ADC safety profiling in NHP models. Also Human/Cyno ortholog proteins for cross-reactivity screening. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (Biosimilars) included with sequence-verified exactness. |
| False Positive Elimination | Validated siRNA Set included for target-specificity confirmation in screening cascades. |
Live SLC34A2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLC34A2 (NaPi-IIb / NPT2b) therapeutics is intensifying, spanning oncology and rare disease. In oncology, major players are shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) targeting ovarian cancer and non-small cell lung cancer (NSCLC). As first-generation therapies reach the clinic, the next wave of R&D is optimizing linker-payload stability and tumor penetration to overcome toxicity hurdles. Simultaneously, the therapeutic potential is expanding into lung-specific disorders: SLC34A2 expression restricted to type II pneumocytes makes it attractive for lung adenocarcinoma ADCs and for phosphate transport inhibition in idiopathic pulmonary fibrosis (IPF). Beyond oncology, gene therapy approaches are under investigation for pulmonary alveolar microlithiasis (PAM), a rare genetic disorder caused by SLC34A2 mutations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Mersana Therapeutics, Rebus, Emerging Biotechs, Lung Cancer Consortiums | Ovarian Cancer, NSCLC, Lung Adenocarcinoma, Solid Tumors | Internalization Assay & Recycling Kinetics (Requires full-length Lentivirus stable lines with native topology) |
| Bispecific Antibody | Emerging Biotechs, Immunotherapy Innovators | Solid Tumors, Lung Cancer | Heterodimer Validation (Need High-Purity ECD) & Cross-reactivity Panel (Human/Cyno/Mouse) |
| CAR-T | Academic Consortia | Refractory Ovarian | Target Engagement (Need Sequence-Verified Controls) |
| Small Molecule Inhibitors | Pharma Research Divisions | Idiopathic Pulmonary Fibrosis (IPF) | Selectivity Assay: SLC34A2 vs SLC34A1 (Need ortholog protein panel to avoid renal toxicity) |
| Gene Therapy | Rare Disease Focused Biotechs | Pulmonary Alveolar Microlithiasis (PAM) | Expression Validation (High-titer Lentivirus for transduction efficiency studies) |
Therapeutic Indications Overview
SLC34A2 is emerging as a versatile target with high tissue specificity. Ovarian cancer (high surface expression) and lung adenocarcinoma (type II pneumocytes) are the primary oncology indications. Non-oncology applications include IPF (phosphate transport inhibition) and PAM (gene replacement). The distinct expression profile enables targeted delivery with reduced systemic side effects, but also demands rigorous isoform selectivity (especially vs SLC34A1) and cross-species tools for preclinical safety evaluation.